

 Early Warning System

EIB-20220917

AKKERMANSIA (IEU LS)



Quick Facts

Countries	Belgium
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2023-08-02
Borrower	The Akkermansia Company SA
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 21.89 million
Loan Amount (USD)	\$ 21.89 million
Project Cost (USD)	\$ 45.96 million



Project Description

As stated by the EIB, the project covers research, development and innovation activities (RDI), including clinical trials, RDI management as well as the early commercialisation expenses of the borrower, aiming at exploiting the unique properties of Akkermansia muciniphila, a bacteria that prevents and reverses leaky gut, a root cause of many health conditions.

The project objectives are to generate data on the efficacy of Akkermansia muciniphila, optimise manufacturing processes and support early commercialisation activities.



Investment Description

- European Investment Bank (EIB)



Private Actors Description

As stated by the EIB, The Akkermansia Company S.A. was founded in 2016 as a spin-off of the UCLouvain and Wageningen University. It is a Belgian microbiome company built on the unique properties of the commensal bacterial species *Akkermansia muciniphila* whose research is focused on demonstrating the key role the bacteria can play in reinforcing gut barrier functions. The company has launched a first product 'Weight Management with Glucose Control' in the EU in 2022 and more recently a second product 'Gut Support with Stress Management' and will continue to add products to its range and to focus on R&D.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	The Akkermansia Company SA	Client	Education and Health



Contact Information

No project contacts provided at the time of disclosure.

Client - The Akkermansia Company SA:

Email: info@theakkermansiacompany.com

Website: <https://www.theakkermansiacompany.com/?v=d2cb7bbc0d23>

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



Bank Documents

- [Environmental and Social Data Sheet](#)

Media

- [Belgium: InvestEU - €20 million EIB venture debt financing to support microbiome research and develo](#)
- [Image 1](#)
- [Image 2](#)
- [Image 3](#)
- [Image 4](#)
- [Image 5](#)
- [Image 6](#)
- [Image 7](#)
- [Image 8](#)
- [Image 9](#)



Other Related Projects

- EIB-20220302 LIFE SCIENCES (INVESTEU VD) PL